[Radioimmunoassay of serum and CSF myelin basic protein and its application to patients with acute cerebrovascular accident].
Myelin basic protein (MBP) was measured in the serum and CSF of patients with acute cerebrovascular disease (CVD, 34 cases), demyelinating disorders (DMD, 30 cases) and other neurological diseases (OND, 26 cases) by using a double antibody radioimmunoassay (RIA). Patients with acute CVD had a mean serum MBP concentration and positivity rate much higher than those with DMD and OND. The differences were significant (P < 0.05). In CSF, MBP levels in patients with acute CVD and patients with DMD were significantly greater than those in OND patients (P < 0.05). The results also show that there was a linear relationship between the CSF MBP levels and the serum MBP levels in patients with acute CVD (r = 0.72, P < 0.01), but no such relationship in patients with DMD and OND. The amount of serum MBP was also significantly correlated to the severity of acute CVD, to the level of consciousness disorder and limb paralysis, and to the extent and site of the cerebral lesion at CT-scan (P < 0.05). This study shows that the measurement of brain specific MBP in serum as a marker of cerebral damage may have clinical value in the diagnosis and prognosis of patients with CVD.
Zhou
L
L
Hu
C
C
Yuan
G
G
Xu
W
W
Chen
J
J
Lai
L
L
D002543:Cerebral Hemorrhage / Q000378:metabolism; D002544:Cerebral Infarction / Q000378:metabolism; D002561:Cerebrovascular Disorders / Q000378:metabolism*; D006801:Humans; D009103:Multiple Sclerosis / Q000378:metabolism; D004676:Myelin Basic Protein / Q000378:metabolism*; D011129:Polyradiculoneuropathy / Q000378:metabolism; D011863:Radioimmunoassay
D004676:Myelin Basic Protein